Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $22.97M
• Dividend Yield: N/A
• Average Volume (3M): 15.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: -29.82%
• EPS Growth: -2.57%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 10,245
• 30 Day Avg. Volume: 15,564
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 45.47
• Enterprise Value/Revenue: 2.21
• Enterprise Value/Gross Profit: -12.93
• Enterprise Value/Ebitda: -3.20
• 1Y Price Target: $5.00
• Price Target Upside: -3.66% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: $5.00 ▼(-3.66% Downside)

Concord Medical Services' overall stock score is primarily impacted by its severe financial distress, with persistent losses and negative cash flows. Technical indicators also suggest a bearish trend, while poor valuation metrics further weigh down the score.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

How the Company Makes Money

Concord Medical Services generates revenue primarily through the provision of radiotherapy services to cancer patients. The company earns income from patient treatment fees, which include charges for the use of advanced medical equipment and facilities. Additionally, CCM has established several key partnerships with medical device manufacturers, allowing it to lease cutting-edge technology and equipment to its centers, further contributing to its revenue stream. The leasing agreements and technical service contracts also provide a consistent source of income, while collaborations with government healthcare programs and hospitals enhance the company’s market presence and patient referral base.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is experiencing severe financial difficulties, with declining revenue, negative gross profit, and EBIT margins. The balance sheet is heavily leveraged with negative stockholders' equity, indicating high risk and solvency issues. Cash flows are also negative, underscoring the critical need for strategic restructuring or capital infusion.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 5.31, below the 50-day MA of 5.72, and below the 200-day MA of 5.45, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 48.41 is Neutral, neither overbought nor oversold. The STOCH value of 23.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	54 Neutral	$16.83M	11.72	-9.49%	―	26.61%	-156.30%
TOI	54 Neutral	$343.16M	―	-535.24%	―	17.53%	14.49%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.76%	-2.28%
MODV	48 Neutral	$33.59M	―	-951.52%	―	-0.70%	-2.38%
CCEL	48 Neutral	$33.11M	380.00	93.38%	9.73%	1.10%	98.13%
PIII	44 Neutral	$49.88M	―	-138.17%	―	4.20%	-54.16%
CCM	39 Underperform	$22.97M	―	14.03%	―	-29.82%	-2.57%